We are live on
!
Find out more
GT Biopharma
GTBP
GTBP
42 hedge funds and large institutions have $657K invested in GT Biopharma in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
76% more capital invested
Capital invested by funds: $374K → $657K (+$283K)
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
11% more funds holding
Funds holding: 38 → 42 (+4)
0.57% more ownership
Funds ownership: 4.54% → 5.11% (+0.57%)
Holders
42
Holders Change
+4
Holders Change %
+10.53%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
7
Reduced
5
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$150K |
| 2 |
AAP
Arax Advisory Partners
Denver,
Colorado
|
+$51.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$25.1K |
| 4 |
I
INVST
Indianapolis,
Indiana
|
+$12.8K |
| 5 |
KP
Keel Point
Huntsville,
Alabama
|
+$11.3K |
Top Sellers
| 1 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$43K |
| 2 |
Jane Street
New York
|
-$20.4K |
| 3 |
HF
HRT Financial
New York
|
-$9K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$8.51K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.96K |
